Investors with a lot of money to spend have taken a bullish stance on Pfizer PFE.
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PFE, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 17 options trades for Pfizer.
This isn't normal.
The overall sentiment of these big-money traders is split between 58% bullish and 41%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $28,162, and 16, calls, for a total amount of $1,095,490.
Projected Price Targets
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $25.0 to $30.0 for Pfizer during the past quarter.
Insights into Volume & Open Interest
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Pfizer's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Pfizer's significant trades, within a strike price range of $25.0 to $30.0, over the past month.
Pfizer Option Volume And Open Interest Over Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| PFE | CALL | SWEEP | BEARISH | 02/23/24 | $26.00 | $384.4K | 31.1K | 4.8K |
| PFE | CALL | SWEEP | BULLISH | 02/23/24 | $26.00 | $106.2K | 31.1K | 1.0K |
| PFE | CALL | SWEEP | BULLISH | 02/23/24 | $26.00 | $89.5K | 31.1K | 1.6K |
| PFE | CALL | SWEEP | BULLISH | 01/17/25 | $30.00 | $81.5K | 27.8K | 835 |
| PFE | CALL | SWEEP | BULLISH | 02/23/24 | $26.00 | $49.8K | 31.1K | 11 |
About Pfizer
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Pfizer's Current Market Status
- Currently trading with a volume of 17,131,549, the PFE's price is down by -2.13%, now at $27.07.
- RSI readings suggest the stock is currently may be approaching oversold.
- Anticipated earnings release is in 77 days.
Professional Analyst Ratings for Pfizer
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $45.0.
- An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $45.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Pfizer, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
